Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

MIRM - Mirum Pharmaceuticals Inc Stock Price, Fair Value and News

$44.56-0.47 (-1.04%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MIRM Price Action

Last 7 days

0.9%

Last 30 days

-10.8%

Last 90 days

6.5%

Trailing 12 Months

63.9%

MIRM Stock Price

MIRM RSI Chart

JunJulAugSepOctNovDec2025FebMar20304050607080

MIRM Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-25.1

Price/Sales (Trailing)

6.55

EV/EBITDA

-39.2

Price/Free Cashflow

236.51

MIRM Price/Sales (Trailing)

2022202320242025510152025303540

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MIRM Fundamentals

MIRM Revenue

Revenue (TTM)

336.9M

Rev. Growth (Yr)

42.93%

Rev. Growth (Qtr)

10%

202220232024050M100M150M200M250M300M350M

MIRM Earnings

Earnings (TTM)

-87.9M

Earnings Growth (Yr)

33.28%

Earnings Growth (Qtr)

-67.12%

20202021202220232024-150M-100M-50M

MIRM Profitability

Operating Margin

75.77%

EBT Margin

-25.80%

Return on Equity

-38.97%

Return on Assets

-13.11%

Free Cashflow Yield

0.42%

MIRM Investor Care

Shares Dilution (1Y)

4.28%

Diluted EPS (TTM)

-1.85

MIRM Alerts

Revenue Breakdown

As of: Dec 31, 2024
2023202420M40M60M80M100M
Product
ProductValuePercent
BusinessValuePercent
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2022AprJulOct2023AprJulOct2024AprJulOct050M100M150M200M250M300M350M
Net sales
YearQ1Q2Q3Q4
2024224.0M264.4M307.0M336.9M
202395.8M115.8M144.7M186.4M
202233.6M48.1M62.6M77.1M
202100019.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
 CEO
 WEBSITEmirumpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES213

Mirum Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Mirum Pharmaceuticals Inc? What does MIRM stand for in stocks?

MIRM is the stock ticker symbol of Mirum Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirum Pharmaceuticals Inc (MIRM)?

As of Wed Mar 12 2025, market cap of Mirum Pharmaceuticals Inc is 2.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIRM stock?

You can check MIRM's fair value in chart for subscribers.

Is Mirum Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MIRM is over valued or under valued. Whether Mirum Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Mirum Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIRM.

What is Mirum Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 12 2025, MIRM's PE ratio (Price to Earnings) is -25.1 and Price to Sales (PS) ratio is 6.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIRM PE ratio will change depending on the future growth rate expectations of investors.